Senior insider sale
CHIEF FINANCIAL OFFICER at ENLIVEN THERAPEUTICS, INC. — senior position signals high conviction
$292.9K
10K shares
What this filing means
HOHL BENJAMIN plans to sell 10K shares of ENLIVEN THERAPEUTICS, INC. valued at approximately $292.9K. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 3/6/2026ACC: 0001974158-26-000022
Officer· CHIEF FINANCIAL OFFICER
Since Feb 2026
10K
Shares to sell
$292.9K
Approx. market value
10K
Acquired (3 months)
1
Planned
Securities Acquired — Last 3 Months1
Long shares from previous exercised options
N/A
12/13/2024
10KTotal acquired10K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
12/13/2024 | Long shares from previous exercised options N/A | 10K | — |
| Total | 10K | ||
Planned & Completed Dispositions1
NasdaqPlanned
Units to sell
10K
Market value
$292.9K
3/6/2026
Total
Units
10K
Value
$292.9K
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
3/6/2026 | 10K | $292.9K | Nasdaq | Planned |
| Total | 10K | $292.9K | ||